COVID-19 Clinical Resources and Pertinent Research
A regularly updated list of the most useful COVID-19 clinical resources, the most significant research publications, and reliable news. To contribute, click the plus button on the left. Short URL: bit.ly/C19Res

Treatment and Management Research

  1. Resources
    1. Assessment of Evidence for COVID-19-Related Pharmacological Treatments
    2. NIH COVID-19 Treatment Guidelines (Rx Summary)
    3. BMJ Living WHO Guideline on Drugs for COVID-19
    4. IDSA Overview of COVID-19 Treatment Guidelines (Image Format)
    5. BMJ Drug Treatments for COVID-19: Living Systematic Review and Network Meta-Analysis
    6. JAMA Review Pathophysiology, Transmission, Diagnosis, and Treatment of COVID-19 (7/20)
    7. UW COVID-19 Treatment, Trails, and Teaching Guide
    8. Global Coronavirus COVID-19 Clinical Trial Tracker

  2. Clinical Management
    1. NIH Summary of Recommendations for the Care of Critically Ill Patients With COVID-19
    2. Therapeutic Dose Anticoagulation Is Associated with a Reduced Need for Mechanical Ventilation and Possibly Death in Hospitalized Moderately Ill Patients but Not in Critically Ill Patients
    3. Pathogenesis of Cytokine Storm in COVID-19
    4. Prone Positioning May Improve Oxygenation in Select Patients
    5. Cardiopulmonary Resuscitation is Ineffective in Hospitalized COVID-19 Patients in Cardiac Arrest
    6. Other
  3. Anti-SARS-CoV-2 Monoclonal Antibodies (mAbs)
    1. NIH Recommendations on Anti-SARS-CoV-2 Monoclonal Antibodies (Data Table / mAb Clinical Summary)
    2. IDSA Recommends on the Use of mAbs in COVID-19 Patients
    3. Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016)
      1. NIH Recommendations on the Use of Bamlanivimab/Etesevimab for the Treatment of COVID-19
      2. FDA Bamlanivimab/Etesevimab Fact Sheet for Health Care Providers
      3. Brief19, REBEL EM, JAMA, PulmCrit (1), and PulmCrit (2) Summaries of Bamlanivimab Data
      4. Preliminary Findings – Bamlanivimab Ineffective As Monotherapy for the Treatment of COVID-19
    4. Casirivimab/Imdevimab (REGN10933/REGN10987; REGN-COV2)
      1. FDA Casirivimab/Imdevimab Fact Sheet for Health Care Providers
      2. Preliminary Findings
    5. See ASHP’s Assessment of Evidence for COVID-19-Related Treatments – SARS-CoV-2-Specific Monoclonal Antibodies

  4. Convalescent Plasma
    1. Convalescent Plasma Treatment Is Not Associated with Improved Survival or Other Positive Clinical Outcomes

  5. Effective and Investigational Pharmacological Treatments (WHO Diagram / NIH Diagram)
    1. Corticosteroids
      1. IDSA Recommendations on the Use of Dexamethasone in COVID-19
      2. Dexamethasone Appears to the Reduce Mortality in Severe and Critical COVID-19
      3. Inhaled Corticosteroids Do Not Appear to Increase Mortality in Patients with Asthma, Caution Still Required
    2. Favipiravir
      1. Clinical Trials
      2. Preliminary Findings
    3. Famotidine
      1. Clinical Trials
      2. IDSA Recommendations on the Use of Famotidine in COVID-19
      3. Preliminary Findings
    4. Ivermectin
      1. NIH Recommendations on the Use of Ivermectin for the Treatment of COVID-19
      2. IDSA Recommendations on the Use of Ivermectin for the Treatment of COVID-19
      3. Merck (Ivermectin Manufacturer) Recommends Against the Use of Ivermectin for the Treatment of COVID-19
      4. Clinical Trials
      5. REBEL EM Summary of the Evidence
      6. Preliminary Findings
    5. Interleukin-6 Inhibitors
      (Tocilizumab, Sarilumab)
      1. NIH Recommendations on the Use of Tocilizumab for the Treatment of COVID-19
      2. Clinical Trials
      3. PulmCrit: Review of 6 Tocilizumab RCT’s
      4. Tocilizumab Combined with Corticosteroids Appears to Marginally Reduce Mortality In Hospitalized Patients with COVID-19 Pneumonia (O2 Sats <92% on Room Air or Require O2) and Evidence of Systemic Inflammation (CRP ≥75mg/L)
      5. Tocilizumab and Sarilumab Are Ineffective As Monotherapy for the Treatment of COVID-19
    6. Other
      1. Almitrine
      2. Baricitinib
      3. Camostat Mesylate
      4. Colchicine
      5. Estradiol
      6. Host-Dirceted Therapies
      7. Inhaled Interferon Beta-1a
      8. Peginterferon Lambda

  6. Ineffective Pharmacological Treatments
    1. WHO SOLIDARITY Trial
      1. Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon Appear to Have Little or No Effect on Hospitalized COVID-19, As Indicated by Overall Mortality, Initiation of Ventilation, and Duration of Hospital Stay
    2. Remdesivir
      1. WHO Recommends Against the Use of Remdesivir in COVID-19
      2. Remdesivir Does Not Appear to Improve Clinical Status or Outcome in COVID-19
    3. Hydroxychloroquine / Chloroquine
      1. NIH Recommends Against the Use of Hydroxychloroquine or Chloroquine in COVID-19
      2. Contextual Commentary: Of Chloroquine and COVID-19
          In past research, chloroquine has shown in vitro activity against many different viruses, but no benefit in animal models. Chloroquine has been proposed several times for the treatment of acute viral diseases in humans without success.
      3. Hydroxychloroquine and Cholorquine are Ineffective as Prophylaxis for or the Treatment of COVID-19 and are Cardiotoxic
    4. Lopinavir–Ritonavir
      1. NIH Recommends Against the Use of Lopinavir/Ritonavir in COVID-19
      2. Lopinavir-Ritonavir is Ineffective in the Treatment of COVID-19
Share